Peripartum cardiomyopathy (PPCM) is a form of heart failure (HF) with poorly understood aetiology, occurring between the last trimester of pregnancy and up to the first five to six months postpartum. 1, 2 Despite an early definition, 3 later modified by Pearson and colleagues, 4 there is no consensus regarding PPCM as a single entity among the leading cardiology societies. 5 The European Society of Cardiology recently declared PPCM a distinct disease entity, 1 although it may take time before wider awareness of PPCM facilitates more timely diagnosis and pro-active treatment. This is unfortunate given that PPCM causes left ventricular (LV) dysfunction, is more common in particular populations (e.g. African women 6 ) and is associated with poor clinical outcomes and survival rates. 7, 8 Some studies suggest the incidence of PPCM is one in 3 000 live births. However, one African study found it to be one in 1 000 live births. 9 There is also a very high risk of relapse in subsequent pregnancies, 10, 11 even following full recovery of LV function after the first pregnancy. 6 Therefore, early and definitive diagnosis of PPCM is essential to limit the high risk of morbidity and mortality in both current and subsequent pregnancies.
Definitive diagnosis and subsequent management of PPCM requires a high index of suspicion. It also usually requires referral to a tertiary centre for echocardiographic studies and specialist cardiological management. Anecdotal evidence suggests that many women who initially present with signs and symptoms indicative of PPCM are diagnosed with 'non-specific symptoms of the puerperal period'. The misdiagnosis of PPCM (often leading to clinical deterioration and in some instances death) represents a clear target for early intervention and prevention. Until specific aetiologies are identified, PPCM remains a diagnosis of exclusion.
Women in their peripartum period suspected with PPCM require rigorous investigation; a costly and laborious process for the patient and healthcare provider. This is particularly difficult in a resource-poor environment. Although screening with (point-ofcare derived) brain natriuretic peptide (BNP) levels may offer a means of detecting elevated atrial pressures secondary to systolic dysfunction (particularly given the age of those affected 6, 12, 13 for example, technical and cost issues remain that prohibit their use. In settings such as sub-Saharan Africa where resources are scarce but the incidence of PPCM is high, the advantages of finding alternative screening tools for this condition that truncate the need for more extensive investigations, while being simple and inexpensive to apply, are abundantly clear. 2, 14 Although there is a paucity of electrocardiographic data specifically relating to PPCM, an 'abnormal' 12-lead electrocardiogram (ECG) is common in individuals with HF syndrome, with common anomalies including supraventricular arrhythmias, bundle branch block, and sinus bradycardia. 15 Given the above, we undertook a prospective, pilot study of the 12-lead ECG in a consecutive cohort of newly diagnosed women with PPCM in South Africa. Specifically, the primary aim of this study was to describe the baseline ECG characteristics in PPCM patients, noting the type and prevalence of major and minor ECG abnormalities. We also sought to analyse six-month follow-up ECGs (where available) of PPCM patients to determine potential ECG correlates of persistent LV dysfunction and/or clinical stability, where possible, as repeat ECGs are not part of the routine follow up of PPCM patients.
Methods
Consecutive patients presenting with de novo PPCM to two tertiary centres in South Africa (Chris Hani Baragwanath Hospital, Johannesburg, and Groote Schuur Hospital, Cape Town) between January 2003 and August 2008 were studied. Patients were referred from primary and secondary health facilities, as well as internally from other departments. Only patients aged ≥ 17 years who fulfilled the diagnostic criteria for PPCM 4 were considered eligible for the study. For recruitment, previously described 16 inclusion and exclusion criteria had to be met.
Ethical approval was obtained from each of the local ethical committees of the universities of Cape Town and the Witwatersrand, respectively, prior to the commencement of the study. This study complied with all the requirements of the Declaration of Helsinki. All patients were offered treatment and follow up as per the local standard of tertiary care.
A total of 78 women presenting with PPCM were studied. Of these, 56% had follow-up ECG data and were included in the comparative study analyses. Of those patients who had not had six-month ECGs (n = 34), three patients died (3.9%). Importantly, patients with repeat six-month ECG data did not differ significantly with respect to baseline heart rate, NYHA functional class, and left ventricular ejection fraction (LVEF) from the remaining cohort.
All patients with the provisional diagnosis of PPCM underwent a thorough medical interview and examination, and were investigated to confirm the diagnosis at baseline. All patients had a 12-lead ECG and echocardiography. Additional investigations were performed on a case-by-case basis. Data were captured on standardised case report forms.
A 12-lead resting ECG was performed by a trained technician and analysed by a reviewer blinded to all clinical data (GL), using the Minnesota code classification system. 17 The code allows systematic classification of Q and QS patterns, axis deviation, R waves, ST depression and elevation, T-wave changes, along with conduction abnormalities in both atria and ventricles. 17, 18 The abnormalities detected by the Minnesota code were pooled into major abnormalities and minor variations from the 'normal' 12-lead ECG using the classification system previously applied by de Bacquer and colleagues 19 ( Table 1) . Separate analyses for ST-segment depression, arrhythmia or atrio-ventricular (AV) block, bundle branch block and left-axis deviation were also performed.
Standard methods for two-dimensional Doppler transthoracic echocardiography were applied as per the American Society of Echocardiography guidelines. 20 LV systolic dysfunction was defined by echocardiographic documentation of left ventricular ejection fraction (LVEF) ≤ 45%. All studies were saved onto hard-drive facilities, and a random sample of these was reviewed by a cardiologist blinded to the clinical details of these patients, to confirm the accuracy of parameters describing cardiac structure and function.
Statistical analyses
All data analyses were performed with STATA-8. 21 For numerical variables, we report on the mean [standard deviation (SD)] results Table 2 summarises the clinical and demographic profiles of the 78 women with de novo PPCM, 10 of whom experienced a firstever detected episode of mildly raised blood pressure at some stage during the index pregnancy. The case report and Fig. 1 describe such a typical case. Interestingly, no patients under the age of 17 years presented to either study unit and 90% of patients included were young women of African ancestry. Of the 10% that were of non-black African ethnicity, almost all were of mixed ancestry, with only one Caucasian patient. The majority of respondents were normotensive and experienced onset of symptoms in the postpartum period (median 18 days, IQR 6-30 days). However, 8% of respondents reported the onset of symptoms prepartum, of which only two were hypertensive (one mild and the other with moderate hypertension, defined as per standard protocol). Table 3 summarises baseline ECG abnormalities/variations from normal (n = 78). The majority of cases (90%) were in sinus rhythm, although mean heart rate was markedly elevated, with 45% of cases in sinus tachycardia (defined as those ≥ 100 beats/ min, given that our patients' maximum heart rate was 134 beats/ min). Only three patients (4%) had completely normal ECGs; excluding those with an elevated heart rate, this increased to nine patients (12%). Overall, 49% (95% CI: 37-60) of cases had a major Minnesota ECG abnormality detected, while 62% (95% CI: 51-74) had a minor ECG variant. A combined total of 63 (81%; 95% CI: 70-89%) cases had one or both forms of abnormality detected on their 12-lead ECG. Of the major abnormalities, major T-wave anomalies (38%), followed by abnormal QRS axis (26%) were the most common (Fig. 2) . T-wave anomalies were also the most common of all documented ECG abnormalities overall (59%), followed by atrial abnormalities (29%).
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Univariate analysis showed no association between LV systolic function and baseline ECG readings. However, on adjustment for age, functional class, echocardiographic LV dimensions, and all the other ECG parameters listed in Table  3 , major T-wave abnormalities correlated negatively with left ventricular systolic dysfunction. The presence of major T-wave changes was associated with a clinically relevant 9% (95% CI: 1-16; p = 0.03%) reduction in LVEF compared to those without T-wave changes.
At six months, a number of clinical parameters had improved in surviving cases subjected to study follow up (n = 44) (Table 4) . Overall, 55% had no residual evidence of LV systolic dysfunction (p < 0.001), although 10% still reported functional impairment (NYHA class II or more). Overall, 25% of this sub-set of cases had a normal 12-lead ECG at six months.
Case report: the ECg in PPCM
Our patient presented to hospital one week after giving birth through spontaneous vaginal delivery, reporting a fiveweek history of shortness of breath equivalent to New york heart Association functional class II, two-pillow orthopnoea associated with cough, bilateral leg swelling, and mild dizziness. On further interrogation, there was a positive family history of sudden 'unexplained' death of her grandmother. Our patient denied any consumption of alcohol or tobacco products.
Clinical examination revealed central and peripheral signs of fluid overload. The pulse rate was 92 beats per minute, this being weak, with occasional irregularities suggestive of ventricular extrasystoles. her blood pressure was 97/72 mmhg, her apex beat displaced laterally, and the abdominal examination proved there to be tender hepatomegaly. Positive findings on cardiac auscultation included a loud, split, second heart sound, and systolic murmur best heard over the mitral and tricuspid areas. Chest auscultation revealed bilateral basal crepitations.
Chest X-ray demonstrated four-chamber cardiomegaly and pulmonary congestion, while her ECG abnormalities included right-axis deviation, with poor R-wave progression and diffuse T-wave inversion (Fig. 1a) . Echocardiography showed dilated cardiac chambers, markedly reduced systolic ventricular function (EF 35%), moderate to severe functional mitral regurgitation, trace tricuspid regurgitation, and a small clear pericardial effusion. Tissue Doppler imaging revealed no further evidence of diastolic dysfunction.
Further tests permitted the exclusion of other common causes of dilated cardiomyopathy, as well as important differential diagnoses. The working diagnosis remained that of peripartum cardiomyopathy.
The patient was started on carvedilol, enalapril, spirinolactone and furosemide. Given the high risk for thromboembolic phenomena presented with the ejection fraction of 35% and below, she was started on warfarin. Despite being seen several times in between, six weeks later she continued to manifest the subtle arrhythmia of moderate-frequency ventricular extrasystoles, with suboptimal heart rate control; hence digoxin was introduced.
Following regular follow-up visits, after six months she reported that she was well, without any heart-failure symptoms. her blood pressure had normalised to 113/64 mmhg and heart rate to 58 beats/min, while the pulse rhythm remained irregular as if with ventricular extrasystoles (now at low frequency). The mitral regurgitation murmur had diminished to grade 1. On ECG, the axis had now normalised, and although there remained diffusely inverted T-waves, their depths had improved, and this inversion normalised in limb lead I. The patient now qualified for left ventricular hypertrophy by voltage criteria using this same lead I (Fig. 1b) . Echocardiography showed persistent but improved Lv dilatation, minimal functional tricuspid and mitral regurgitation, with improvement of Lv systolic function to an EF of 49%.
According to univariate analyses, no difference between 'clinically stable/responded to treatment' (i.e. recovered LV function) versus non-responders (persistent LV dysfunction)
were found in respect of any ECG parameter. However, on an adjusted basis, major T-wave changes and major ST-segment depression found on the baseline 12-lead ECG subsequently correlated with persistently impaired systolic function at six months. Specifically, the presence of major T-wave changes at baseline was associated with a markedly lower LVEF at six months (-12%, 95% CI: -4 to -21; p = 0.006) compared to those without T-wave changes at baseline. In addition, ST-segment elevation at baseline was associated with an even greater reduction in LVEF at six months (-25%, 95% CI: -0.7 to -50; p = 0.044) compared to those without this ECG pattern at baseline.
discussion
To the best of our knowledge, this is the first study to systematically describe the 12-lead ECG in de novo cases of PPCM. Our main aim was to examine the potential utility of the 12-lead ECG (a relatively inexpensive and easy-to-apply diagnostic tool) in detecting underlying LV dysfunction in confirmed cases of de novo PPCM in African women. This would require a high underlying level of ECG abnormalities in such a cohort in order to discriminate against (presumably) more normal 12-lead ECGs in African women experiencing healthier pregnancies.
Of the 78 cases studied, 49% demonstrated major ECG abnormalities, usually associated with significant underlying cardiac pathology, while 62% demonstrated one or more forms of minor variation/abnormality, potentially indicative of the same. We also attempted to examine whether the 12-lead ECG is a useful tool for discriminating between those cases who respond to treatment (by the resolution of initially observed ECG abnormalities) and those who had persistent LV dysfunction. In this respect, we found that the presence of two major abnormalities (T-wave inversion and ST-segment depression) and a third Minnesota code criterion not listed as one of the major or minor criteria (ST-segment elevation) found on the baseline Typically, LV systolic functional recovery in PPCM is a slow and drawn-out process that enters the second year of treatment. 2 On this basis, while LVEF in those patients subjected to six-month follow up improved overall, just under half still had defined impaired LV dysfunction, and this represents a major therapeutic target for treatment. Therefore, long-term follow up using the ECG in PPCM might well show ECG reversal to normality as late as 18 months after first diagnosis, as our long-term echocardiographic data suggest. 8 Moreover, we have identified potentially useful markers (i.e. major T-wave inversion and/or ST-segment depression on the 12-lead ECG) as simple but important prognostic markers that might trigger more intensive/ aggressive treatment and follow up in PPCM cases.
Our findings and the overall utility of the 12-lead ECG in this clinical setting require careful interpretation when fundamental investigations such as echocardiography remain inaccessible to most hospitals and patients in sub-Saharan Africa. Serum levels of NT-proBNP are known to strongly predict the degree of heart failure, 12 yet this test is still not available in most referral hospitals in Africa where PPCM is prevalent. Surprisingly, because of vast differences in sensitivity and specificity in detecting HF, it has been suggested that the overall cost-effectiveness of measuring serum NT-proBNP becomes comparable to that of screening for HF using the 12-lead ECG alone, 25, 26 due mainly to the relatively low specificity of the 12-lead ECG. 26 The scarcity of the serum NT-proBNP test in our setting almost mandates using something as inexpensive and easy as the 12-lead ECG to screen for PPCM, even if its sensitivity and specificity prove to be imperfect. These data will be particularly useful if (after comparing ECG patterns in healthy African women, derived from the Heart of Soweto cohort 27 ) the 12-lead ECG has the potential to be applied as a 'rule-out' test (i.e. high specificity to identify all truly negative for PPCM cases). Unfortunately, the ability to combine 12-lead ECG with typical symptoms of HF (to increase its accuracy in detecting PPCM) is confounded by their parallel presence in the late stages of pregnancy (but not typically post-partum).
As indicated, our data suggest that baseline major T-wave abnormalities were associated with poorer LV systolic function at baseline, and, alongside baseline ST-segment depression, they were also associated with persistent LV systolic dysfunction in the short to medium term (i.e. six months). In Western countries, major ST-segment depression and T-wave abnormalities are often regarded as indications of myocardial ischaemia, bearing consistent prognostic significance for cardiovascular disease mortality across prospective studies, especially for men. 28 We remain wary of the fact that gender differences in ECG findings often show women to have a higher prevalence of ST-segment depression or T-wave changes, such as to question the true significance of any association between ST-segment depression and T-wave abnormalities with coronary heart disease (CHD) mortality in women. 28 However, we are greatly reassured by the number of large, population-based studies that show major 
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ST-depression to be the most predictive ECG characteristic of cardiovascular disease (CVD) and CHD mortality, lending an average two-fold risk of CVD and CHD mortality, and, as with our study, predicting these outcomes from their mere presence at baseline. 19 Studies reporting on the ECG in prognostication of PPCM remain scarce, with two from Nigeria suggesting it to be a weak predictor of recovery and long-term prognosis in PPCM. 29, 30 However these studies did not use echocardiography to confirm the diagnosis of PPCM, 30 and had a greater proportion of patients with hypertension than those without. 29, 30 Given recent insight that patients with the PPCM phenotype who present with hypertension appear to follow a different natural history to those without, 2 any comparisons between data from PPCM patients with hypertension with those without hypertension should be interpreted with great caution.
Systematic reports of ECG abnormalities associated with idiopathic dilated cardiomyopathy (IDCM), which bears some resemblance to PPCM, are few. One such study of IDCM reported that the ECG was found to be normal in up to 25% of affected relatives of IDCM patients (who by definition suffer from familial DCM), although these were not all newly diagnosed IDCM cases. 31 Hence, as in our study, an overwhelming majority had abnormal ECGs.
It remains fair to say that the shortage of studies systematically reporting on the prevalence of ECG anomalies in PPCM may account for most for our inability to corroborate our findings with other available evidence, yet no reports contradict our findings. Overall, therefore, our data can only suggest that the 12-lead ECG in PPCM may be sensitive to underlying LV dysfunction and/or that it can serve as a marker of more extensive cardiac insult early in the disease process.
Lastly, we note that the 1% prevalence of first-degree heart block, usually not considered to bear any significant risk to adverse CVD outcome, except for its association with lamin A/C mutation in familial DCM, may in our PPCM cohort merely reflect the 1-2% prevalence in normal young adults. 32 However, after recent reports implicating this so-called benign form of heart block in the general population with increased risk of atrial fibrillation and adverse CVD outcome 20 years down the line, 32 and suggestions that post-exercise measurements of PR intervals may be more prognostic within five-year follow-up periods than resting ECG PR intervals, 32 it would be useful to revise the prognostic implications of first-degree heart block post exercise in patients with underlying myocardial disease and congestive cardiac failure as in PPCM.
Furthermore, evaluation of this conduction disorder may be of particular importance in PPCM, in view of several reports of first-degree AV block being among one of the earliest signs of lamin A/C mutation, which in turn commonly leads to a phenotype of apparently unexplained DCM. 33 It is worth considering that the prognostic implications behind each of the criteria for major and minor ECG abnormalities/variants derived from the Minnesota code appear more applicable in the screening of high-risk persons only, 34 as in this clinical context. This pilot study has a number of limitations that require comment. Firstly, the Minnesota code may not be sufficiently validated for the detection of heart disease in pregnant women. Moreover, the 'normal' 12-lead ECG in African women is yet to be definitively described. Whether the combined presence (81% of cases) of major abnormalities and minor variations is sufficient to support further investigation of the 12-lead ECG as a screening tool (particularly when there are few data to describe the 'normal' 12-lead ECG in pregnant and non-pregnant African women), is open to debate.
In determining the sensitivity of ECG changes over time, relative to underlying LV dysfunction, we had valid data for only 56% of the cohort. Although our PPCM patients who did not have follow-up ECGs did not differ in clinical and echocardiographic outcome from those with follow-up data, the possibility that the former group may have been clinically worse off than those with six-month data cannot be excluded, given that greater proportions of the former manifested minor T-wave anomalies, and that their left ventricular diameters and BMI at baseline appeared greater than those who had six-month ECGs. However, in light of the lower prevalence of QRS-axis deviation and bundle branch block among the former group, interpretation of the similarity of patients with and without follow up with regard to ECG characteristics becomes speculative.
Further data are required to better characterise the 12-lead ECG as a marker of LV dysfunction in this specific clinical (and ethnic) context, before any firm recommendations can be made in respect of obtaining a 12-lead ECG at the conclusion of each pregnancy in sub-Saharan Africa.
Conclusions
Despite a number of limitations, this still represents a unique study that will prove to be invaluable in determining the future role of the 12-lead ECG as an inexpensive and simple 'rule-out' screening tool for PPCM, and perhaps an important tool for increasing the intensity of subsequent treatment and management. Overall, we found the majority (96%) of PPCM patients presented with 'abnormal' 12-lead ECGs, which improved significantly to 75% after the first six months of treatment. Over 80% of patients displayed either major abnormalities or minor variations using the Minnesota code. Of these, sinus tachycardia and QRS-axis deviation were most likely to be attenuated after six months. Even though these ECG abnormalities were mostly non-specific and similar to those of other dilated cardiomyopathies, our study further suggests the ECG to be useful in simple monitoring of clinical progress during treatment and prognostication.
Specifically, the baseline presence of major T-wave and ST-segment abnormalities in the context of PPCM patients may place these patients at similar risk of adverse outcomes to those with myocardial ischaemia. More definitive studies are required to determine if this simple and relatively inexpensive tool will prove to be of particular clinical use in the setting of PPCM. Any progress in this regard will be welcome, given the persistently poor health outcomes associated with PPCM in resource-poor settings.
